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Abstract
A body of translational evidence has implicated dietary deficiency in long-chain omega-3 (LCn-3) fatty acids,
including eicosapenaenoic acid (EPA) and docosahexaenoic acid (DHA), in the pathophysiology and potentially
etiology of different psychiatric disorders. Case–control studies have consistently observed low erythrocyte (red
blood cell) EPA and/or DHA levels in patients with major depressive disorder, bipolar disorder, schizophrenia, and
attention deficit hyperactivity disorder. Low erythrocyte EPA + DHA biostatus can be treated with fish oil-based
formulations containing preformed EPA + DHA, and extant evidence suggests that fish oil supplementation is safe
and well-tolerated and may have therapeutic benefits. These and other data provide a rationale for screening for
and treating LCn-3 fatty acid deficiency in patients with psychiatric illness. To this end, we have implemented a
pilot program that routinely measures blood fatty acid levels in psychiatric patients entering a residential inpatient
clinic. To date over 130 blood samples, primarily from patients with treatment-refractory mood or anxiety disorders,
have been collected and analyzed. Our initial results indicate that the majority (75 %) of patients exhibit whole
blood EPA + DHA levels at ≤4 percent of total fatty acid composition, a rate that is significantly higher than general
population norms (25 %). In a sub-set of cases, corrective treatment with fish oil-based products has resulted in
improvements in psychiatric symptoms without notable side effects. In view of the urgent need for improvements
in conventional treatment algorithms, these preliminary findings provide important support for expanding this
approach in routine psychiatric practice.
Keywords: Long-chain omega-3 fatty acids, Eicosapentaenoic acid (EPA), Docosahexaenoic acid (DHA), Bipolar
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Background
Limited efficacy and adverse side-effects associated with
conventional psychotropic medications used for the treat-
ment of psychitaric disorders highlight an urgent need to
identify modifiable risk and resilience mechanisms to inform
improvements in current treatment algorithms. Over the
past three decades a substantial body of evidence has impli-
cated a dietary deficiency in long-chain omega-3 (LCn-3)
fatty acids, eicosapenaenoic acid (EPA) and docosahexae-
noic acid (DHA), in the pathophysiology of different
recurrent psychiatric disorders, including major depressive
disorder (MDD), bipolar disorder, schizophrenia, and
attention deficit hyperactivity disorder (ADHD). While
this body of evidence has been slow to impact conven-
tional psychiatric training and practice, the field is slowing
evolving and nutritional medicine is gaining credibility [1].
This review provides a brief overview of evidence
implicating LCn-3 fatty acid deficiency in the patho-
physiology and potentially etiology or recurrent psychi-
atric disorders, and then discusses strategies to translate
this evidence into clinical screening and treatment
algorithms. We present preliminary data from a recently
implemented pilot program which routinely measures
blood fatty acid levels in psychiatric patients entering a
residential inpatient clinic. Four notable cases that
illustrate the benefits resulting from detecting and
treating LCn-3 fatty acid deficiency are presented.
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LCn-3 fatty acids
As background, omega-3 (n-3) and omega-6 (n-6) fatty
acids are members of the polyunsaturated fatty acid
(PUFA) family. Prominent dietary sources of the short-
chain n-3 fatty acid precursor α-linolenic acid (ALA,
18:3n-3) include flaxseed, linseed, canola, soy, and perilla
oils. Prominent dietary sources of the short-chain n-6
fatty acid precursor linoleic acid (18:2n-6) include
safflower, soy, and corn oils. These PUFAs are consid-
ered ‘essential’ because mammals are entirely dependent
on dietary sources to procure and maintain adequate
concentrations in peripheral and central tissues. Long-
chain (LC) fatty acids derived from these short-chain
precursors require a series of common and competitive
biosynthetic reactions. In human subjects, however, LC
fatty acid biosynthesis is extremely inefficient, and dietary
intake of preformed LCn-3 and LCn-6 fatty acids is signifi-
cantly more effective for increasing peripheral and pres-
umably central levels [2–6]. Preformed LCn-3 fatty acids
including EPA (20:5n-3) and DHA (22:6n-3) can be
obtained directly from fatty cold water fish, including
salmon, trout, tuna, as well as fish oil and algal-derived
supplements, and preformed LCn-6 fatty acids including
arachidonic acid (AA, 20:4n-6) can be obtained directly
from animal-based foods including beef, chicken, and eggs.
Animal neurodevelopmental studies
Animal studies have provided important insight into the
role of dietary LCn-3 fatty acids in the maturation of
multiple neuronal systems implicated in the pathoetiology
and treatment of psychiatric disorders. The advantage of
animal studies is the ability to systematically and select-
ively manipulate dietary n-3 fatty acid intake and to
control myriad extraneous variables that frequently con-
found interpretation of clinical studies. In general, rodent
feeding studies have demonstrated that cortical accrual of
DHA, the primary LCn-3 fatty acid in mammalian brain,
during perinatal development is positively associated with
cortical neurogenesis [7–9], neuroblast migration [10],
neuronal differentiation [11], neurotrophic factor (NGF,
BDNF) expression [12, 13], nerve growth factor-induced
neurite outgrowth and synaptogenesis [14–17], and synap-
tic pruning [18]. Cortical DHA deficiency during develop-
ment is also associated with neuroinflammation [19], and
an enduring dysregulation in multiple neurotransmitter
systems including dopamine and serotonin which are
reversible with early, but not later, postnatal n-3 fatty acid
supplementation [20, 21]. In addition to neurotrophic and
anti-inflammatory effects, DHA and its bioactive metabo-
lites are protective against a variety of insults associated
with oxidative stress and lipid peroxidation in the fetal
and adult rat brain [22–33]. Behavioral studies suggest
that development deficits in brain DHA accrual are asso-
ciated with elevated behavioral indices of depression that
emerge after puberty [34, 35]. In contrast, dietary fish oil
fortification significantly decreases depression-like behav-
ior similar to antidepressant medications [36, 37]. These
and other data highlight the importance of DHA for
normal brain maturation.
In non-human primates, dietary-induced n-3 fatty acid
deficiency during development is associated with deficits
in visual attention [38], polydipsia [39], and deficits in
visual acuity and electroretinogram abnormalities [40, 41].
Electroretinogram abnormalities have also been observed
in neonatal baboons born preterm [42]. Perinatal n-3 fatty
acid deficiency is associated increased home cage stereo-
typy and locomotion bouts [43], which is consistent with
dysregulated mesolimbic dopamine activity. A neuroimag-
ing study found that resting-state functional connectivity
among prefrontal cortical networks was impaired in mon-
keys raised on an n-3 fatty acid deficient diet compared
with monkeys raised on fish oil-fortified diet [44]. Specific-
ally, n-3 fatty acid deficiency during perinatal development
was associated with reduced resting-state connectivity be-
tween the dorsal anterior insula (seed-region) and ventro-
medial, orbitofrontal, and dorsolateral prefrontal regions,
as well as superior temporal and medial parietal regions,
compared with monkeys raised on a fish oil-fortified diet.
A positron emission tomography study demonstrated that
dietary supplementation with DHA improves the decline
in neurovascular coupling observed in aged monkeys [45].
As with rodents, these findings suggest that low cortical
DHA status is associated with a range of enduring neuro-
developmental abnormalities.
Human neurodevelopmental studies
During pregnancy DHA accumulates in human neonatal
brain tissue at an accelerated rate during the third trimes-
ter in association with rapid changes in cortical structural
maturation [46, 47]. Prospective longitudinal studies have
observed a positive relationship between fetal cord
blood DHA levels and neurodevelopmental outcomes
in older children [48–54]. As observed in non-human
primates [55], human infants born preterm exhibit lower
erythrocyte and postmortem cortical DHA concentrations
compared with term infants [56–60]. Preterm birth and/
or low birth weight is associated with increased risk for
developing ADHD in childhood [61–63], and mood, anx-
iety, and psychotic disorders during adolescence and
young adulthood independent of maternal history of
psychiatric illness [64–69]. Studies also suggest that longer
breastfeeding duration, a putative surrogate for early post-
natal DHA intake, is associated with better neurocognitive
outcomes [70–72] and decreased risk for ADHD [73–76].
Recent neuroimaging findings suggest that low LCn-3 fatty
acid intake and biostatus may impair cortical structural and
functional maturation in corticolimbic regions repeatedly
implicated in psychopathology [77–86]. Together these
Messamore and McNamara Lipids in Health and Disease  (2016) 15:25 Page 2 of 13
findings suggest that early and uncorrected deficits in DHA
accrual during development are associated with suboptimal
brain development and may increase risk of psychopath-
ology emerging in childhood and adolescence.
Relevance to psychopathology
Epidemiological evidence
Cross-national epidemiological surveys have observed a
significant inverse correlation between per capita fish or
seafood consumption (primary dietary sources of pre-
formed EPA +DHA) and lifetime prevalence rates of
MDD [87, 88], postpartum depression [89], and bipolar
spectrum disorders [90]. While the prevalence rates of
schizophrenia appear to be consistent across different
countries and not associated with per capita fish or
seafood consumption [88], functional outcomes are
better in counties with higher per capita intake of vege-
tables, fish or seafood [91]. There is also large cross-
national variation in the prevalence rates of ADHD, with
lower rates being observed in Asian countries compared
with Western counties [92]. Cross-sectional studies simi-
larly suggest that habitual diets low in LCn-3 fatty acids
are associated with increased prevalence rates of depres-
sive symptoms in adolescents [93–96]. A retrospective
study found that the shift away from fish-based to
Western diets in Arctic communities was associated
with increased rates of seasonal affective disorder, de-
pression, suicide, and cardiovascular disease [97]. While
these findings provide indirect support for an inverse
association between fish-based diets and prevalence rates
of some psychiatric disorders, most notably depression,
myriad variables may also be protective either individu-
ally or in combination with fish intake.
Several lines of evidence also suggest that increasing
LCn-3 fatty acid status may reduce risk of suicide, a
primary cause of excess premature mortality in mood
and psychotic disorders [98–101]. First, cross-sectional
epidemiological surveys have observed an inverse correl-
ation between dietary LCn-3 fatty acid intake and the
prevalence of suicidal ideation in the general population
in Finland [102], and that seasonal variations in violent
suicide rates coincide with seasonal variations in serum
LCn-3 fatty acid levels [103]. In two case–control stud-
ies, erythrocyte or plasma LCn-3 fatty acid levels were
significantly lower in suicidal patients [104, 105], and a
prospective surveillance study found that low baseline
plasma DHA composition was a significant predictor of
future suicidal attempts in medication-free patients with
MDD [106]. Two controlled trials found that chronic
(12 week) dietary LCn-3 fatty acid treatment reduced
suicidality in MDD patients [107, 108]. However,
prospective cohort studies conducted in the United
States (U.S.) have not observed an association between
LCn-3 fatty acid intake and completed suicide in the
general population [109]. Therefore, while extant evi-
dence suggests that increasing LCn-3 fatty acid status in
patients with psychiatric illness may be protective
against suicidality, additional research is needed to
evaluate whether depressed mood mediates this effect.
Excess premature mortality in patients with mood and
psychotic disorders is also attributable in part to
cardiovascular-related diseases [98–101], and associated
risk factors are apparent early in the course of illness (i.e.,
in adolescents)[110]. Multiple lines of evidence suggest
that LCn-3 fatty acid deficiency may increase risk for car-
diovascular disease morbidity and mortality [111]. Cross-
national epidemiological studies have observed reduced
prevalence rates of coronary heart disease morbidity and
mortality in populations whose habitual diets include fish
[112]. Fatty acid composition studies have found an in-
verse correlation between erythrocyte EPA +DHA levels
and cardiovascular risk factors including elevated serum
triglyceride and pro-inflammatory molecules [113, 114].
LCn-3 fatty acid supplementation is efficacious for the
treatment of elevated serum triglyceride levels, an inde-
pendent risk factor for cardiovascular disease, and pre-
scription fish oil-based products have been approved by
the U.S. Food and Drug Administration (FDA) for the
treatment of hypertriglyceridemia [115]. Prospective stud-
ies suggest that low baseline erythrocyte EPA +DHA
(‘omega-3 index’) levels are associated with increased risk
of sudden cardiac arrest [116–118]. It is relevant, the-
refore, that the low erythrocyte EPA +DHA levels
observed in patients with mood and psychotic disorders
are similar to those observed in patients suffering acute
coronary syndrome [119], and would be anticipated to in-
crease their risk for sudden cardiac arrest (Fig. 1). While
the effects of LCn-3 fatty acid supplementation on
cardiovascular events and sudden cardiac arrest in pa-
tients with a history of cardiovascular disease have
been equivocal [120], primary prevention studies in
subjects without a history of cardiovascular disease
[121] or subjects at high-risk for cardiovascular dis-
ease [122] suggest that increasing LCn-3 fatty acid
biostatus may have protective benefits. While there
have been no LCn-3 fatty acid primary prevention
studies conducted in patients with mood or psychotic
disorders, existing evidence provides a rationale for
identifying and treating LCn-3 fatty acid deficiency in
psychiatric patients, particularly those presenting with
cardiovascular risk factors.
Biological evidence
Cross-national habitual dietary fish intake is positively
correlated with erythrocyte membrane EPA +DHA
composition [123, 124], and fish oil supplementation in-
creases erythrocyte EPA + DHA composition in a linear
dose-dependent manner [125]. Several independent case–
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control studies from different countries have investigated
erythrocyte and/or plasma phospholipid EPA +DHA
levels in patients with psychiatric disorders. A meta-
analysis of 14 case–control studies found significant defi-
cits in EPA and DHA in plasma and erythrocytes from
MDD patients [126]. In bipolar patients, four studies
observed significant erythrocyte DHA and/or EPA defi-
cits compared with healthy controls [127–130]. Cross-
sectional studies have similarly found that pediatric and
adolescent patients with or at ultra-high risk for mood
disorders exhibit erythrocyte EPA +DHA deficits com-
pared with healthy youth [131–134]. Robust erythrocyte
EPA +DHA deficits were also observed in non-depressed
patients with social anxiety disorder [135], and plasma
EPA +DHA deficits were observed in MDD patients with
comorbid anxiety disorders [136]. Medication-naïve first-
episode psychotic patients exhibit erythrocyte DHA and
AA deficits compared with healthy controls [137–139],
and a recent meta-analysis of 18 case–control studies ob-
served significant DHA and AA deficits in schizophrenic
patients [140]. A recent meta-analysis of nine cross-
sectional studies observed significantly lower blood
EPA + DHA levels in ADHD children compared with
healthy controls [141]. Together, these studies provide
strong evidence that different psychiatric disorders are
characterized by low blood DHA and/or EPA biosta-
tus which coincides with, and may precede, the initial
onset of psychopathology.
Adult human erythrocyte and frontal cortex DHA levels
are positively correlated [142], and a growing number of
case–control studies have investigated the fatty acid com-
position of postmortem frontal gray matter from patients
with psychiatric disorders. Some studies have observed
lower LCn-3 fatty acid levels [143–147] while others have
not [148–150]. Limitations associated with the postmor-
tem approach may contribute to discrepant results [151].
Nevertheless, emerging evidence from neuroimaging stud-
ies provide support for a positive association between
LCn-3 fatty acid intake or blood levels on cortical struc-
tural and functional integrity over the lifespan [77–86].
For example, greater habitual dietary LCn-3 fatty acid in-
take, which is positively correlated with erythrocyte EPA
+DHA composition, was associated with larger cortical
gray matter volumes in several corticolimbic regions in-
cluding the anterior cingulate cortex, hippocampus, and
amygdala [83]. It is relevant, therefore, that patients with
psychiatric disorders commonly exhibit gray matter vol-
ume deficits in the anterior cingulate cortex, hippocam-
pus, and amygdala [152–154]. Moreover, a recent study
found that fish oil supplementation increased white mat-
ter microstructural integrity in MDD patients in associ-
ation with reductions in depression symptom severity
[155]. Together these findings suggest that there may be a
link between low LCn-3 fatty acid biostatus and deficits in
corticolimbic structural and functional integrity observed
in patients with psychiatric disorders.
LCn-3 fatty acid supplementation
Dietary LCn-3 fatty acid supplementation has been found
to significantly increase erythrocyte LCn-3 fatty acid levels
in different patient populations [138, 156–158]. This ob-
servation indicates that LCn-3 fatty acid deficits in psychi-
atric patients are modifiable by increasing dietary LCn-3
fatty acid intake. Meta-analyses of controlled trials suggest
that LCn-3 fatty acid supplementation may be effective for










































Fig. 1 Comparison of mean EPA +DHA levels in adult patients with acute coronary syndrome (ACS) residing in the U.S. (erythrocytes, n = 768) [119],
first-episode bipolar disorder (BD) (erythrocytes, n = 40) [130] and adolescent MDD (erythrocytes, n = 20) [134] patients residing in the Cincinnati area,
psychiatric patients admitted to the inpatient clinic at The Lindner Center of HOPE, Cincinnati (whole blood, n = 131), normative values from a cohort
subjects residing in the U.S. (whole blood, n = 27,414, http://www.omegaquant.com/fatty-acids-regularly-measured/), and adults residing in Japan
(erythrocytes, n = 456) [124]. Proposed ‘risk zones’ for sudden cardiac death derived from prospective longitudinal studies are indicated [118]. Note that
psychiatric patients exhibit EPA + DHA levels that are similar to patients with ACS and place them at high risk for sudden cardiac arrest. It is proposed
that similar ‘risk zones’ be adopted in psychiatric practice to identify patients requiring corrective LCn-3 fatty acid supplementation
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ADHD patients [141, 159]. Accumulating evidence sug-
gests that LCn-3 fatty acid supplementation may be effica-
cious for the treatment of positive and negative symptoms
in patients with or at ultra-high risk for developing schizo-
phrenia [156, 160, 161], and for preventing or delaying the
onset of psychosis in ultra-high risk youth [156]. A recent
meta-analysis of controlled trials suggests that LCn-3 fatty
acids may be efficacious during the prodromal stage and
in first-episode psychotic patients but not in patients with
chronic schizophrenia [162]. These data suggest that early
correction of LCn-3 fatty acid deficits may have greater ef-
ficacy compared with treatment initiated following
chronic illness.
Preliminary trials have found that LCn-3 fatty acid sup-
plementation, either as monotherapy or adjunctive treat-
ment, significantly reduces depression and manic symptom
severity in pediatric and adolescent patients [134, 157, 158,
163]. Meta-analyses of controlled trials have observed a sig-
nificant advantage of LCn-3 fatty acid supplementation over
placebo for reducing depressive symptoms in patients with
MDD [164, 165] or bipolar disorder [166]. A recent meta-
analysis conducted on controlled trials employing exclu-
sively adult MDD patients observed a small-modest bene-
fit for reducing depressive symptoms [167]. In the latter
study, the authors concluded that this effect was unlikely
to be clinically meaningful and that existing evidence was
low quality. Indeed, heterogeneity in study design in terms
of daily dose, EPA:DHA ratio, trial duration, concomitant
psychotropic medications, use of a bioactive placebo (i.e.,
olive oil), sample size, and baseline symptom severity
likely contribute substantial variability. It is also important
to recognize that neurostructural and neurochemical per-
turbations resulting from LCn-3 fatty acid deficiency
during development may not be reversible with short-
term supplementation. This is supported by rodent studies
finding that enduring impairments in serotonin and dopa-
mine neurotransmission resulting from perinatal n-3 fatty
acid deficiency are reversible with early but not later n-3
fatty acid supplementation despite normalization of LCn-
3 fatty acid biostatus [20, 21]. Therefore, detection and
treatment of LCn-3 fatty acid deficiency early in the
course of illness may be required to exert the greatest
protection against recurrent depressive symptoms.
In many controlled LCn-3 fatty acid intervention studies
observing benefits for depressive symptoms, patients were
also receiving conventional antidepressant medications.
This suggests that adjunctive LCn-3 fatty acid treatment
may augment the therapeutic efficacy of antidepressant
medications. This is directly supported by studies compar-
ing selective serotonin reuptake inhibitor (SSRI) treatment
with or without adjunctive LCn-3 fatty acids in patients
with MDD. In these studies, adjunctive LCn-3 fatty acid
treatment augmented the therapeutic efficacy of fluoxetine
[168] or citalopram [169]. Additionally, adjunctive LCn-3
fatty acid treatment was found to reduce depression
symptom severity in adolescent and adult MDD patients
that were refractory to standard antidepressant treatment
[108, 134]. Adjunctive LCn-3 fatty acid treatment was also
found to reduce relapse rates in predominantly medicated
adult patients with bipolar disorder [170], and to reduce
manic symptom severity in medicated pediatric patients
with bipolar disorder [158]. In patients with first-episode
psychosis, adjunctive LCn-3 fatty acid (EPA) treatment
accelerated treatment response, improved tolerability, and
permited a 20 percent reduction in second-generation
antipsychotic medication dose [171]. In addition to aug-
menting efficacy, adjunctive LCn-3 fatty acid treatment
may also be protective against adverse cardiometabolic
[172–174] and hepatic [175–177] side-effects associated
with second generation antipsychotic medications.
These preliminary findings suggest that adjunctive
LCn-3 fatty acid treatment may augment therapeutic
efficacy and mitigate cardiometabolic side-effects asso-
ciated with conventional psychotropic medications.
Implementation
In the previous sections we briefly summarized a body of
translational evidence which suggests that LCn-3 fatty
acid deficiency, particularly during perinatal development,
may represent a modifiable risk factor for psychopath-
ology. Among these findings, meta-analyses of independ-
ent case–control studies demonstrate that patients with
different psychiatric disorders, including mood, psychotic,
and attentional disorders, exhibit significantly lower blood
levels of EPA and/or DHA compared with healthy demo-
graphically similar controls. Additionally, meta-analyses of
several independent controlled intervention studies sug-
gest that increasing EPA +DHA biostatus via dietary
supplementation with fish oil-based products may be
effective for reducing psychiatric symptoms, suicidality,
and cardiometabolic risk factors. Together these and other
data support routine screening for and treatment of LCn-
3 fatty acid deficiency in patients with psychiatric disor-
ders. Below we briefly discuss existing screening and treat-
ment resources and general guidelines required for
implementation in psychiatric practice.
Diagnosing LCn-3 fatty acid deficiency
There are currently several Clinical Laboratory Improve-
ment Amendments (CLIA)-certified laboratory facilities
that routinely perform blood fatty acid analyses by
gas–liquid chromatography (GLC). While the American
Medical Association has several current procedural ter-
minology (CPT) codes for blood fatty acid analysis by
GLC (82725, 82544, 82492) and GLC testing in general
(82541, 82542), reimbursement for these tests is ultimately
at the discretion of the insurance provider. For this
procedure, whole blood (~25 uL) is obtained from a finger
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prick and is spotted and dried onto anti-oxidant treated
card which is then shipped at ambient temperature. The
GLC analysis involves the determination of different fatty
acids including EPA +DHA which are reported as a per-
centage of total fatty acids. Fatty acid levels are returned
to the physician in approximately 2 weeks. Individual fatty
acid levels can be compared to U.S. population norms.
Against this reference, a patient’s fatty acid levels can be
expressed in a percentile ranking. Based on evidence that
erythrocyte EPA +DHA composition of ≤4 % of total fatty
acid composition increases risk for sudden cardiac death
[118], and evidence that the majority of patients with psy-
chiatric disorders exhibit erythrocyte EPA + DHA com-
position of ≤4 % [128, 130, 132, 134, 178], erythrocyte or
whole blood EPA+DHA composition of ≤4 % may be con-
sidered to be a ‘state of deficiency’ that requires corrective
intervention. Analogous to routine cholesterol testing, this
screening approach can provide a valid, reliable, and rela-
tively non-invasive measure of a patient’s EPA +DHA
biostatus.
Treating LCn-3 fatty acid deficiency
Prescription ethyl ester EPA +DHA (Lovaza® in the US,
Omacor® in Europe, GlaxoSmithKline), purified ethyl ester
EPA containing no DHA (Vascepa®, Amarin Corporation),
and a free versus ethyl ester EPA +DHA formulation
(Epanova®, AstraZeneca) have been approved by the
U.S. FDA for the treatment of hypertriglyceridemia
(≥500 mg/dL). More recently a generic version of Lovaza
has become available (Teva Pharmaceuticals USA, Inc.).
Over-the-counter fish oil supplements containing similar
ethyl ester EPA +DHA concentrations are also widely
available. It is important to note, however, that no LCn-3
fatty acid formulation is currently approved by the FDA
for the treatment of any psychiatric disorder.
The American Psychiatric Association has adopted the
consensus recommendations of the American Heart
Association for an EPA +DHA dose of 1 g/d in patients
with MDD [179]. The American Heart Association also
recommends 3 g/d EPA +DHA for reducing elevated
triglyceride levels. Controlled intervention studies have
in general found that daily doses in the range of 0.2–2 g/
d of EPA +DHA may be efficacious for the treatment of
mood symptoms [164, 165]. Emerging evidence also sug-
gests that a larger ratio of EPA to DHA may be more ef-
ficacious for treating depressive symptoms [165] as well
as ADHD symptoms [159]. A dose–response study
found that EPA +DHA supplementation at doses be-
tween 300–900 mg/d are sufficient to increase eryth-
rocyte EPA +DHA composition in non-psychiatric
subjects to levels thought to be cardioprotective [125].
As with other medications, upward dose titration may
be required as clinically indicated. For example, in an
open-label flexible dosing study 8-week LCn-3 fatty acid
monotherapy led to a statistically significant reduction in
manic symptom severity scores in pediatric bipolar pa-
tients [157]. In this study the starting dose was 1.3 g/d
of EPA +DHA, the maximum dose was 4.3 g/d, and the
mean dose was 2.6 g/d. While there is a need for add-
itional dose-titrating secondary prevention trials to eluci-
date optimal LCn-3 fatty acid dosing strategies to
maximize therapeutic effects, existing evidence suggests
that EPA +DHA doses in the range of 1–4 g/d are suffi-
cient to treat erythrocyte EPA +DHA deficits in patients
with psychiatric illness.
The U.S. Food and Drug Administration (FDA) con-
siders LCn-3 fatty acid doses up to 3 g/d to be ‘generally
regarded as safe’. Potential adverse events associated
with LCn-3 fatty acid treatment include gastrointestinal
disturbances, including nausea, diarrhea, gastroesopha-
geal reflux, eructation, and less commonly emesis. In
double-blind clinical trials in adolescent and adult
patients, the principal adverse events reported after
chronic (8–12 weeks) treatment with LCn-3 fatty acid
supplements were gastrointestinal problems, and were
considered mild and not clinically significant [134, 158,
163, 179]. To minimize the gastrointestinal adverse
events associated with LCn-3 fatty acids, patients should
be instructed to take their pills with meals. Although
taking fish oil at high doses (>3 g/d) has been associ-
ated in isolated cases with increased bleeding time in
subjects also taking anticoagulant medications [180],
controlled clinical trials have found that chronic high
dose EPA +DHA alone or in combination with aspirin
does not increase risk for clinically-significant increases in
bleeding time [181–183]. Another safety consideration
involves the potential threat of contamination of fish and
seafood with methyl mercury and other environmental
pollutants. However, most fish oil supplements are highly
purified and do not exceed U.S. FDA limits for methyl
mercury and other environmental contaminants. As with
all medications, patients should be informed of poten-
tial risks associated with fish oil-based products, and
patients with an allergy to shellfish or seafood should
be closely monitored.
Proof-of-concept
The Lindner Center of HOPE (http://www.lindnercen-
terofhope.org) is a university-affiliated mental health
care center located in Mason, a suburb of Cincinnati,
Ohio. The center houses an outpatient mental health
clinic, acute care hospital services, and specialized resi-
dential diagnostic assessment programs. The residential
diagnostic assessment programs serve approximately 280
pediatric, adolescent, and adult patients annually. Patients
are typically referred to these programs by mental health
clinicians when there is diagnostic uncertainty, and mul-
tiple treatment failures is the most frequent cause of
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diagnostic uncertainty. Complex affective or anxiety di-
sorders are the most common reasons for referral. Diag-
nostic assessment within these programs includes medical
examination, neurological examination, laboratory studies,
brain imaging or EEG when indicated, neuropsychological
testing, objective personality assessment, structured diag-
nostic interview, serial mental status evaluations, continu-
ous behavioral observations in the residential milieu, and
acquisition of collateral behavioral histories from families,
close associates, or outpatient healthcare providers.
Beginning in mid-2014, measurement of whole blood
fatty acid levels was implimented as part of the routine
laboratory assessment. Dried blood spots are sent to
OmegaQuant, LLC for analysis. To date over 131 patient
blood samples have been collected and analyzed. The
majority of these patients were referred for mood or
anxiety disorders and had previously responded poorly
to standard outpatient care (i.e., treatment-refractory).
Our initial results suggest that the majority (75 %) of
patients exhibit whole blood EPA + DHA levels at ≤4
percent of total fatty acid composition. This rate is
significantly greater than general U.S. population norms
(25 %) based on 27,414 subjects residing in the U.S.
(p ≤ 0.0001) (Fig. 2a). The overall (n = 131) EPA +DHA
mean for patients is 3.2 % of total fatty acid composition,
which is at the 8th percentile of fatty acid norms and
lower than the mean observed for the general U.S. popula-
tion (5.1 %, 25th percentile) (Fig. 2b). It is notable that the
mean EPA +DHA level observed in psychiatric patients is
similar to that observed in erythrocytes from U.S. adult
patients suffering acute coronary syndrome (3.4 %)[119]
(Fig. 1), which places them at elevated risk for developing
sudden cardiac arrest [118]. Our initial results therefore
support prior evidence that psychiatric patients exhibit
very low EPA +DHA levels. Below we describe four
notable cases that illustrate the benefits resulting from
detecting and treating LCn-3 fatty acid deficiency.
Clinical vignettes
Case 1
A 24 year old man with childhood onset of psychiatric
symptoms, at least 4 prior psychiatric hospitalizations,
and historical diagnoses of type 2 bipolar disorder, atten-
tion deficit-hyperactivity disorder, eating disorder, and
borderline personality disorder was found to have an
omega-3 index (EPA +DHA) of 2.98 % which placed
him at the 4th percentile of U.S. population norms.
Based on this, he was prescribed Lovaza (ethyl-EPA/
ethyl-DHA) at a daily dose of 1,860 mg EPA and
1,500 mg DHA (total EPA + DHA dose: 3,360 mg/d)
which was covered by his insurer. Based on his history
of bipolar disorder, his divalproex prescription was con-
tinued. However, based on lack of efficacy his vilazadone
and lisdexamphetamine were discontinued. Within three
weeks the patient reported to his outpatient psychiatrist
that his mental status, mood and mood stability, and
overall level of social and occupational functioning were
the best he could ever recall. At 6-month follow-up his
omega-3 index (EPA +DHA) had risen to 7.69 % (85th
percentile), and he reported that he was enjoying a con-
tinued stability previously unknown to him. He credited
his success to the addition of the ethyl-EPA/ethyl-DHA,
stating that he had never had such benefit associated
with divalproex. He also discounted the possibility that
Fig. 2 a The percentage of subjects residing in the U.S. (n = 27,426) and psychiatric patients admitted to the inpatient clinic at The Lindner
Center of HOPE (n = 131) with an ‘omega-3 index’ (whole blood EPA + DHA) of ≤4.0 % of total fatty acid composition. b Histogram comparing
‘omega-3 index’ (EPA + DHA) frequency distribution of the psychiatric patient sample to the OmegaQuant reference sample. Note that the
majority (75 %) of psychiatric patients exhibit whole blood EPA + DHA levels at ≤4 percent of total fatty acid composition, a rate that is
significantly greater than general U.S. population norms (25 %, ***P ≤ 0.0001, Chi-Square)
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discontinuation of his antidepressant and stimulant medi-
cations were relevant, since there had been many prior
episodes of being off these medications with no recalled
equal benefit.
Case 2
A 27 year old woman was admitted with a chief com-
plaint of emotional dysregulation. Although there was a
family history of bipolar disorder, the patient had no
history of manic episodes; however, she did engage in
frequent suicidal gestures and self-injurious behaviors.
The patient also had experienced simple partial seizures
since early childhood. Her omega-3 index (EPA +DHA)
was 2.93 % of total fatty acids (3rd percentile). Based on
the family history of bipolar disorder, lithium was added
to her existing medications. Her topiramate and oxcar-
bazapine were continued. Based on the low level of
omega-3 fatty acids, she was also started on Lovaza
(ethyl-EPA/ethyl-DHA) at a dose of 1860/1500 mg daily
(total EPA +DHA: 3,360 mg/d). Consistent with recent
evidence that fish oil supplementation elevates seizure
thresholds and reduces seizure frequency in epileptic
patients [184, 185], at six-month follow-up she had been
seizure-free, was able to live independently and reported
no self-injurious behaviors.
Case 3
A 23 year old man was referred for treatment because he
was contemplating suicide because he could no longer
tolerate near-constant depression and anxiety. He had
suffered from severe anxiety since age 5. He had been
treated with a wide variety of antidepressant medications,
mood stabilizers, and stimulants since his early teens.
Medications had been either ineffective or poorly toler-
ated. He was diagnostically enigmatic and over the course
of his life had been diagnosed with anxiety disorder, major
depression, bipolar disorder, and attention deficit hyper-
activity disorder. Comprehensive diagnostic assessment
suggested generalized anxiety disorder and bipolar dis-
order not otherwise specified as the most appropriate
diagnoses. Fatty acids analysis revealed an omega-3 index
of 3.38 % (11th percentile). Because of this, addition of
omega-3 fatty acids to his medications was recommended.
He took an over-the-counter fish oil supplement at a dose
that delivered 1600 mg of EPA and 800 mg of DHA per
day (total EPA +DHA: 2,400 mg/d). Other treatment
recommendations included: discontinuation of serotonin
reuptake inhibitors, addition of lithium, and addition of a
low dose of topiramate (50 mg nightly). He was continued
on his existing 200 mg nightly dose of quetiapine. At
nine-month follow-up, he reported markedly improved
social and occupational functioning and normalization of
his mood. The durability of his improvements allowed for
elimination of lithium and topiramate and halving of his
quetiapine dose. He continued to take the EPA+DHA
supplement.
Case 4
A 38 year old woman reported constitutively high anx-
iety levels since childhood and also described highly
reactive mood and difficulty managing anger, and identi-
fied anxiety as her most pressing concern. She had tried
numerous serotonin reuptake inhibitor medications with
no discernable benefit. She reported a history of prob-
lematic use of alcohol and benzodiazepines, though she
had not used either substance for several months prior to
her assessment. She was diagnosed with anxiety disorder,
not otherwise specified; benzodiazepine abuse in early full
remission; and alcohol abuse in early full remission.
Borderline personality traits were prominent, but criteria
for a personality disorder diagnosis were not fully met.
Fatty acid analysis revealed an omega-3 index of 3.25 %
(8th percentile). Because serotonergic medications had
been historically unhelpful, she was prescribed topiramate
to address mood reactivity and anxiety, and to promote
sustained abstinence from alcohol, and fish oil supplemen-
tation was recommended. She elected to take an over-the-
counter fish oil supplement at a dose that delivered an
EPA dose of 1080 mg/d and DHA dose of 720 mg/d (total
EPA +DHA: 1,800 mg/d). At three month follow-up, she
reported adherence to recommended dialectical behavior
therapy and had continued to take topiramate (50 mg
twice daily) and the fish oil supplement. She reported
significant and sustained reduction of anxiety, improved
mood stability, abstinence from alcohol or benzodiaze-
pines, and improved social and interpersonal functioning.
Conclusions
There is now a substantial body of translational evidence
that suggests that LCn-3 fatty acid deficiency, particularly
during active periods of brain development, is associated
with neuropathogenic features that have separately been
implicated in the pathophysiology of different psychiatric
disorders. Moreover, major recurrent psychiatric disorders
are associated with blood LCn-3 fatty acid deficiency
which may increase risk for cardiovascular disease, a
principle cause of excess premature mortality in patients
with mood and psychotic disorders. Extant evidence sug-
gests that LCn-3 fatty acid supplementation is sufficient to
increase LCn-3 fatty acid blood levels in psychiatric
patients which may additionally have therapeutic benefits
and mitigate adverse cardiometabolic risk factors. These
and other data provide a strong rationale supporting
routine screening for and treatment of LCn-3 fatty acid
deficiency in patients with psychiatric illness. As proof-of-
concept, we have demonstrated the feasibility of imple-
menting blood LCn-3 fatty acid screening as well as
treatment using fish oil-based formulations in a residential
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diagnostic assessment center. Consistent with prior cross-
sectional evidence, our preliminary results demonstrate
that the majority of these patients exhibit very low blood
EPA +DHA levels, and that treatment with fish oil can
result in improvements in psychiatric symptoms without
any notable side effects. Within the context of extant
evidence and the urgent need for improvements in con-
ventional treatment algorithms, these preliminary findings
provide important support for expanding this approach in
routine psychiatric clinical practice.
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